Chang-Lei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chang-Lei Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Zu-Sen Wang
The Affiliated Hospital of Qingdao University
2 shared publicationsAo Sun
Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China
1 shared publicationAo-Yun Hao
Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China
1 shared publication- Chenyu Cao
De Anza College, Cupertino, USA
1 shared publication Haozhuo Guo
CAS Key Laboratory of Molecular Imaging Beijing Key Laboratory of Molecular Imaging Institute of Automation Chinese Academy of Sciences Beijing China
1 shared publication- Huadan Xue
Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by Wiley in Advanced Science
- p. e78434
Combined Immune‐Peptide Nanofiber with HSP70/AKT/mTOR Axis Blockade Enhances Photothermal Immunotherapy, Inhibiting Tumor Growth and Recurrence
Although immune checkpoint blockade (ICB) therapies have shown clinical benefit, ICBs exert limited effects on most “immune‐cold” solid tumors, i.e., tumors with low immune infiltration. Photothermal immunotherapy (PTIT) converts “cold” tumors into “hot” tumors, thereby enhancing immune responses and improving ICB efficacy. Hence, developing a strategy that can integrate PTIT and ICB treatment is desirable. In this study, we designed a unique carrier‐free PSP@IR‐CF 3 nanofiber, self‐assembled from the programmed death‐ligand 1 (PD‐L1) targeting immune‐peptide NTGYFYGDQ (PSP) and a PTIT agent (IR‐CF 3 ). The nanofibers enable precise tumor targeting and immune checkpoint inhibition by specifically binding to PD‐L1 on the tumor cell surface, also providing an NIR‐mediated photothermal effect. Combining PSP@IR‐CF 3 nanofibers with NIR induced mild PTIT, which effectively activated the tumor immune microenvironment and suppressed tumor growth with lower immunotoxicity. Additionally, we identified activation of the heat shock protein 70 (HSP70) /AKT/mTOR axis following PTIT, suggesting a potential role in post‐treatment tumor survival and recurrence. By incorporating the mTOR inhibitor rapamycin, the combination treatment further enhanced therapeutic efficacy and reduced tumor recurrence.
- 25 October 2026
- Published by Wiley in Advanced Science
- p. e78434
Open AccessCombined Immune‐Peptide Nanofiber with HSP70/AKT/mTOR Axis Blockade Enhances Photothermal Immunotherapy, Inhibiting Tumor Growth and Recurrence
Although immune checkpoint blockade (ICB) therapies have shown clinical benefit, ICBs exert limited effects on most “immune‐cold” solid tumors, i.e., tumors with low immune infiltration. Photothermal immunotherapy (PTIT) converts “cold” tumors into “hot” tumors, thereby enhancing immune responses and improving ICB efficacy. Hence, developing a strategy that can integrate PTIT and ICB treatment is desirable. In this study, we designed a unique carrier‐free PSP@IR‐CF 3 nanofiber, self‐assembled from the programmed death‐ligand 1 (PD‐L1) targeting immune‐peptide NTGYFYGDQ (PSP) and a PTIT agent (IR‐CF 3 ). The nanofibers enable precise tumor targeting and immune checkpoint inhibition by specifically binding to PD‐L1 on the tumor cell surface, also providing an NIR‐mediated photothermal effect. Combining PSP@IR‐CF 3 nanofibers with NIR induced mild PTIT, which effectively activated the tumor immune microenvironment and suppressed tumor growth with lower immunotoxicity. Additionally, we identified activation of the heat shock protein 70 (HSP70) /AKT/mTOR axis following PTIT, suggesting a potential role in post‐treatment tumor survival and recurrence. By incorporating the mTOR inhibitor rapamycin, the combination treatment further enhanced therapeutic efficacy and reduced tumor recurrence.
- Open Access
- 1 July 2026
- Published by SAGE Publications in Science Progress
- Vol. 109 (3)
Antihypertensive drug targets and pancreatitis reporting signals: An integrative mendelian randomization and FAERS pharmacovigilance study
Objective: To investigate whether genetically proxied antihypertensive drug targets are associated with pancreatic exocrine diseases and whether corresponding antihypertensive agents show pancreatitis-related pharmacovigilance signals. Methods: This integrative genetic epidemiology and pharmacovigilance study combined linkage disequilibrium score regression, two-sample Mendelian randomization, summary-data-based Mendelian randomization, Bayesian colocalization, and FAERS disproportionality analysis. Publicly available GWAS summary statistics were derived predominantly from European-ancestry participants, and whole-blood cis-eQTLs were used to genetically proxy antihypertensive drug-target expression. FAERS reports submitted from 2004 to 2023 were analyzed for pancreatitis-related reporting signals. Results: Among 21 antihypertensive drug targets, ADRB2, CACNA1I, JUN, NR3C2, and SLC12A4 showed nominal associations with pancreatic outcomes; however, none remained significant after Bonferroni correction. Absolute PP.H4 values did not support robust colocalization. Although several target-outcome pairs had high conditional PP.H4 values, these findings provide only relative support for H4 over H3 when both traits are assumed to have regional association signals. Several antihypertensive agents also generated pancreatitis-related reporting signals in FAERS; these signals do not quantify incidence or establish causality. Conclusions: The findings are exploratory and prioritize selected antihypertensive targets and drugs for replication and mechanistic study. They do not establish causal effects, robust colocalization, or an increased incidence of pancreatitis.
- 1 July 2026
- Published by SAGE Publications in Science Progress
- Vol. 109 (3)
Open AccessAntihypertensive drug targets and pancreatitis reporting signals: An integrative mendelian randomization and FAERS pharmacovigilance study
Objective: To investigate whether genetically proxied antihypertensive drug targets are associated with pancreatic exocrine diseases and whether corresponding antihypertensive agents show pancreatitis-related pharmacovigilance signals. Methods: This integrative genetic epidemiology and pharmacovigilance study combined linkage disequilibrium score regression, two-sample Mendelian randomization, summary-data-based Mendelian randomization, Bayesian colocalization, and FAERS disproportionality analysis. Publicly available GWAS summary statistics were derived predominantly from European-ancestry participants, and whole-blood cis-eQTLs were used to genetically proxy antihypertensive drug-target expression. FAERS reports submitted from 2004 to 2023 were analyzed for pancreatitis-related reporting signals. Results: Among 21 antihypertensive drug targets, ADRB2, CACNA1I, JUN, NR3C2, and SLC12A4 showed nominal associations with pancreatic outcomes; however, none remained significant after Bonferroni correction. Absolute PP.H4 values did not support robust colocalization. Although several target-outcome pairs had high conditional PP.H4 values, these findings provide only relative support for H4 over H3 when both traits are assumed to have regional association signals. Several antihypertensive agents also generated pancreatitis-related reporting signals in FAERS; these signals do not quantify incidence or establish causality. Conclusions: The findings are exploratory and prioritize selected antihypertensive targets and drugs for replication and mechanistic study. They do not establish causal effects, robust colocalization, or an increased incidence of pancreatitis.
- Open Access
- 12 June 2026
- Published by Association for Computing Machinery (ACM)
- p. 116-120
A Credit Assessment Model Fusing Structured Financial Data and Unstructured Text Based on a Multimodal Attention Mechanism
- 12 June 2026
- Published by Association for Computing Machinery (ACM)
- p. 116-120
Open AccessA Credit Assessment Model Fusing Structured Financial Data and Unstructured Text Based on a Multimodal Attention Mechanism
- Open Access
- 26 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (39) , e44608
Identification of MMEL1 as a novel therapeutic target for primary sclerosing cholangitis: Integrating Mendelian randomization and transcriptome landscapes
Primary sclerosing cholangitis (PSC) is a kind of cholestatic liver disease without effective targeted therapies, and its pathogenesis remains largely unclear. We performed genome-wide Mendelian randomization analysis to identify therapeutic targets PSC risk. Summary statistics for PSC were obtained from 2 datasets: the International PSC Study Group (2871 cases and 12,019 controls) and the FinnGen cohort (1483 cases and 361,641 controls). Cis-expression quantitative trait loci for druggable genes were extracted from the eQTLGen Consortium and Genotype-Tissue Expression Version 8 database and applied as genetic instrumental variables. Colocalization analysis was performed to estimate the probability that single nucleotide polymorphisms associated with PSC and eQTLs shared causal locus. Six drug targets (APOM, BTN3A2, HLA-DRA, membrane metalloendopeptidase like 1 [MMEL1], NEU1, and RXRB) presented significant Mendelian randomization results in 2 independent datasets. MMEL1, of which eQTLs resourced from blood, liver, transverse colon, and intestine, was all found to have strong evidence for colocalization with PSC. Genetically proxied inhibition of MMEL1 was also detected to attenuate the risk of immune bowel diseases and ulcerative colitis. A transcriptome-wide associated study presented consistent inference, as shown above. Our study highlighted 1 candidate druggable target (MMEL1 for PSC development and prognosis).
- 26 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (39) , e44608
Open AccessIdentification of MMEL1 as a novel therapeutic target for primary sclerosing cholangitis: Integrating Mendelian randomization and transcriptome landscapes
Primary sclerosing cholangitis (PSC) is a kind of cholestatic liver disease without effective targeted therapies, and its pathogenesis remains largely unclear. We performed genome-wide Mendelian randomization analysis to identify therapeutic targets PSC risk. Summary statistics for PSC were obtained from 2 datasets: the International PSC Study Group (2871 cases and 12,019 controls) and the FinnGen cohort (1483 cases and 361,641 controls). Cis-expression quantitative trait loci for druggable genes were extracted from the eQTLGen Consortium and Genotype-Tissue Expression Version 8 database and applied as genetic instrumental variables. Colocalization analysis was performed to estimate the probability that single nucleotide polymorphisms associated with PSC and eQTLs shared causal locus. Six drug targets (APOM, BTN3A2, HLA-DRA, membrane metalloendopeptidase like 1 [MMEL1], NEU1, and RXRB) presented significant Mendelian randomization results in 2 independent datasets. MMEL1, of which eQTLs resourced from blood, liver, transverse colon, and intestine, was all found to have strong evidence for colocalization with PSC. Genetically proxied inhibition of MMEL1 was also detected to attenuate the risk of immune bowel diseases and ulcerative colitis. A transcriptome-wide associated study presented consistent inference, as shown above. Our study highlighted 1 candidate druggable target (MMEL1 for PSC development and prognosis).